{"id":5206,"date":"2021-02-26T21:15:54","date_gmt":"2021-02-27T05:15:54","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=5206"},"modified":"2021-02-26T21:15:54","modified_gmt":"2021-02-27T05:15:54","slug":"interleukin-6-receptor-antagonists-in-critically-ill-patients-with-covid-19-2","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/26\/interleukin-6-receptor-antagonists-in-critically-ill-patients-with-covid-19-2\/","title":{"rendered":"Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19"},"content":{"rendered":"<ul>\n<li>A trial of two IL-6 receptor antagonists, tocilizumab and sarilumab, in critically ill hospitalized adults with confirmed COVID-19 found that in-hospital mortality in the pooled IL-6 receptor antagonist groups was 27% (108 of 395 patients), as compared with 36% (142 of 397 patients) in the group of people receiving standard care, which results in a posterior probability of &gt;99.5% that the treatments improved in-hospital survival. 93% of all patients were treated with glucocorticoids. Both drugs were effective across all secondary outcomes, including 90-day survival and time to ICU and hospital discharge.<span class=\"Apple-converted-space\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i>Gordon et al. (Feb 25, 2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine. <\/i><a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2100433\">https:\/\/doi.org\/10.1056\/NEJMoa2100433<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A trial of two IL-6 receptor antagonists, tocilizumab and sarilumab, in critically ill hospitalized adults with confirmed COVID-19 found that in-hospital mortality in the pooled IL-6 receptor antagonist groups was 27% (108 of 395 patients), as compared with 36% (142 of 397 patients) in the group of people receiving standard care, which results in a&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/26\/interleukin-6-receptor-antagonists-in-critically-ill-patients-with-covid-19-2\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-5206","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=5206"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5206\/revisions"}],"predecessor-version":[{"id":5208,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5206\/revisions\/5208"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=5206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=5206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=5206"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=5206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}